Bioptamers

Executive Summary

Bioptamers Inc. is a privately-held biotechnology company headquartered in Cambridge, Massachusetts, focused on developing personalized precision therapies for cancer using a proprietary aptamer-based drug delivery platform. Founded in 2016, the company aims to address key limitations of monoclonal antibodies and other targeted modalities by leveraging aptamers—short, single-stranded oligonucleotides that bind to specific molecular targets with high affinity. Bioptamers’ approach enables scalable, cost-effective production of targeted therapies designed to identify and treat cancer cells selectively, potentially reducing off-target effects and improving therapeutic indices. The platform is positioned to create a new class of precision oncology medicines that can be rapidly adapted to individual patient profiles, supporting a personalized treatment paradigm. Bioptamers operates in the highly competitive drug delivery space, with a focus on translating its aptamer technology into clinical candidates. While the company has not disclosed specific financial details or pipeline stages, its presence in the Cambridge biotech hub and emphasis on platform innovation suggest it may be advancing toward preclinical validation or early-stage partnerships. The company’s success hinges on demonstrating the in vivo efficacy and safety of its aptamer-drug conjugates, as well as establishing manufacturing scalability. As the field of aptamer therapeutics matures, Bioptamers could emerge as a key player if it can deliver compelling proof-of-concept data and secure strategic collaborations to support further development.

Upcoming Catalysts (preview)

• Q2 2027Lead program IND-enabling studies completion40% success
• Q4 2026Strategic partnership for platform development50% success
• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal70% success